A recent study that showed YAP regulates PD-L1 expression in EGFR-TKI-resistant NSCLC, that gefitinib-resistant PC9 cells (exon 19 deletion mutation) have increased YAP and PD-L1 protein expression when compared to parental PC9 cells, and that YAP knockdown decreased the expression of PD-L1 in gefitinib-resistant PC9 cells [112]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.